Yes you are correct, that shows confidence in growing forward, this year is going to be different for Aray IMO
One study compared the plan quality and delivery efficiency of TomoHelical using TomoEDGE dynamic jaws to TomoHelical fixed jaw delivery mode for nasopharyngeal carcinoma treatments. Results showed equivalent plan quality, with dynamic jaws mode providing a more efficient delivery and better sparing of the optic chiasm, pituitary and parotid glands when compared to fixed jaw delivery mode. An evaluation of stereotactic radiation therapy (:SBRT) for brain metastases using TomoHelical in dynamic jaws mode found treatment time was reduced by 75 percent using this modality compared to treatment with fixed jaw delivery mode.
An additional study of the CyberKnife System for low and intermediate organ-confined prostate cancer showed a high rate of biochemical progression free survival (95.8 percent and 90 percent for low- and intermediate-risk groups, respectively) with acceptable toxicity at a median follow-up of 84 months.
An additional study examined the safety and efficacy of an accelerated dose/fractionation schedule delivered using the CyberKnife System after lumpectomy for selected patients with early-stage breast cancer. With a median follow-up of 27 months all patients remained locally controlled with good to excellent cosmesis and no evidence of disease following treatment.
I agree but in the mean time IMO the share price will rise in anticipation of positive cash flow and order growth. You are correct about China that could be explosive for its market cap, the CEO Josh Levine is delivering.
Yes, next year will be interesting but I am anticipating a higher share climbing before that. It will then be too late for those not buying in now...the woulda, shoulda coulda. NIce to hear from you pauv
SUNNYVALE, Calif., October 15, 2015
Accuray Incorporated (Nasdaq: ARAY) announced today that Kelly Londy, formerly chief commercial officer has been named chief operating officer of the Company effective immediately. Ms. Londy will also remain an executive vice president of the Company.
Kelly has successfully led Accurays Global Commercial Team for the past three years and played a key leadership role in building commercial momentum and improving our financial performance, said Joshua H. Levine, president and chief executive officer. Her expanded responsibilities will provide end-to-end leade rship amongst all customer facing activities, starting with product development and progressing through customer adoption and service, with a continued focus on customer satisfaction and consistent commercial execution.
Ms. Londy joined Accuray in 2011 as its senior vice president and chief commercial officer. Prior to joining Accuray, Londy served as vice president and general manager of Molecular Imaging, at GE Healthcare North America, where she optimized multi-business strategy with a focus on value proposition for improved cost, quality and access to new technologies. She also held roles in marketing, executive account management and as a product specialist in the MR and Womens Health businesses while at GE. Ms. Londy also served as vice president and general manager at Philips Healthcare North America, where she held multiple leadership roles.
growth in equipment used maybe we will see growth in SP when earnings are announced. excellent post hemmerjohn9
Accuray To Report Fiscal 2016 First Quarter Financial Results On October 29, 2015
they are playing catch up, they feel the pressure from Aray, they have the cash to buy Aray
Varian Announces U.S. Clearance and CE Mark for VitalBeam™ Package; Chirayu Medical College in Bhopal Acquires the New Platform for Advanced Radiotherapy